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ABSTRACT 
 
Chronic urticaria (CU) also known as chronic idiopathic urticaria results in a lowered quality of life 
(QoL). Disease specific questionnaires are necessary to assess QoL in CU patients. Chronic Urticaria 
Quality of Life Questionnaire (CU-Q2oL) is the only available and validated disease specific questionnaire 
in the assessment of QoL in CU patients originally developed in Italian language. The aim of the current 
study was to develop the Persian version of the CU-Q2oL with an acceptable reliability and validity. 
Using the standard methods provided by guidelines, CU-Q2oL was translated into Persian. A total 
number of 110 patients with confirmed diagnosis of CU were asked to fill the questionnaire. Determination 
of scales was performed in addition to checking the data for internal consistency and known group validity. 
Urticaria activity score 7 (UAS-7) was used to assess the severity of the CU in the population study. The 6 
dimensional scale of Persian CU-Q2oL was determined using the Exploratory Factor Analysis. About 68% 
of the variance was explained by these 6 factor structure higher than 59.9% of the original Italian version. 
All 6 factors showed acceptable internal consistency as measured by Cronbach α coefficient. There was 
a significant correlation between UAS-7 and total CU-Q2oL score. UAS7 and the presence of  
angioedema were predictors of CU-Q2oL score. 
The Persian version of CU-Q2oL was shown to be a valid and reliable tool to be used in the future 
clinical studies. Cultural considerations must be kept in mind in adoption of CU-Q2oL to other languages.  
 
Keywords: Adaptation; Chronic urticaria; Persian; Quality of life; Questionnaire; Validation  
 
Corresponding Author: Marzieh Tavakol, MD; National 
Research Institute of Tuberculosis and Lung Disease (NRITLD), 
Masih-Daneshvari Hospital, Dar-Abad, Tehran, Iran, Tel. +98 21 
2712 2069, E-mail: tavakol_m@razi.tums.ac.ir 
Persian Chronic Urticaria Quality of Life Questionnaire 
279/ Iran J Allergy Asthma Immunol, Summer 2014                                                                                       Vol. 13, No. 4, August 2014 
Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir) 
INTRODUCTION 
 
Chronic urticaria (CU) also known as chronic 
idiopathic urticaria is a common skin disorder affecting 
about 1 in 100 individuals.
1,2
 It is defined by the 
appearance of itchy wheals with or without angioedema 
in all or most days of the week lasting for at least 6 
weeks
1
 and characterized by periods of remission and 
relapses. Clinical management of CU is a difficult goal 
and the true etiology of CU remains unknown in up to 
90% of cases.
1
 CU patients suffer from physical, social, 
and psychological morbidities resulting in a low quality 
of life.
3-5
 
Assessment of quality of life (QoL) in CU patients 
is a mandatory step in the clinical researches as well as 
the routine management of disease. Researchers shall 
accurately evaluate QoL to achieve an unbiased 
judgment regarding the efficacy of the desired 
treatment.
6
 Physicians also benefit from the assessment 
of QoL in their routine management of CU to provide 
better therapeutic options in order to increase the well 
being of their patients.
6
 
Health-related QoL (HRQoL) is defined as the 
patients’ evaluation of their own well being comparing 
to what they consider as ideal.
7
 Although several 
studies evaluated the impact of CU on the QoL of 
patient, most of them used generic questionnaires 
designed for the assessment of QoL in general such as 
Nottingham Health Profile or in dermatological disease 
like Dermatology Quality of Life Index.
8
 To answer the 
need for a disease specific questionnaire to investigate 
the different aspects of CU on the physical and 
psychological well being of patients, Baiardini et al. 
developed the Chronic Urticaria Quality of Life 
Questionnaire (CU-Q2oL) originally available in 
Italian language.
9
 CU-Q2oL showed good reliability 
and validity both in its original language and when 
translated and adopted in several other languages 
including Brazilian-Portuguese, German, Polish, 
Spanish and Turkish.
3,6,9-12
 
Adaption of CU-Q2oL questionnaire provides a 
suitable tool to compare the result of studies performed 
in various countries on the clinical aspects of CU.
10
 The 
aim of the current study was to develop the Persian 
version of the CU-Q2oL with an acceptable reliability 
and validity. This questionnaire can be used for further 
clinical researches on CU on Persian population as well 
as providing a unified measurement for evaluation of 
QoL in Persian speaking CU patients at the routine 
clinical setting.   
 
MATERIALS AND METHODS 
 
Study Design and Data Collection 
The current study was designed to validate the 
Persian version of the CU-Q2oL questionnaire to be 
used as a measurement tool for QoL in Persian CU 
patients for future studies. CU-Q2oL was originally 
designed in Italy and included 23 items in 6 dimensions 
of quality of life: 2 items about pruritus, 6 items about 
impact on life activities, 5 items about sleep problems, 
3 items about limits, 5 items about looks, and 2 items 
about swelling. Every item could be answered in Likert 
scale by never, rarely, sometimes, often, very often or 
in some occasions by none, a little, moderate, a lot, 
very much. Scores were converted into a 0 to 100 scale. 
A higher score demonstrated a worse HRQoL. 
A total number of 110 patients with a confirmed 
diagnosis of CU were investigated at the department of 
Allergy and Clinical Immunology, Children's Medical 
Center. Diagnosis was confirmed after taking detailed 
medical history and physical examinations. The ethics 
committee of Tehran University of Medical Sciences 
approved the process of this study and informed 
consents were obtained from all patients. Patients were 
asked to fill and return the questionnaire when they 
visited the hospital during their routine follow-up. 
Subjects were also asked to fill and return the same 
questionnaire 1 week after the first visit to check the 
reliability of the evaluation process. Due to social and 
cultural issues, we were unable to use electronic mails 
for the follow-up process and all patients filled and 
returned the questionnaire in our hospital. Patients’ 
demographic data and medical records were also 
reviewed.  
 
Translation of CU-Q2oL into Persian 
The original Italian version of CU-Q2oL was 
adopted into Persian using the standard methodology 
for translation and cross-cultural adoption.
13
 First, 2 
native Persian speakers who were fluent in Italian 
translated the original Italian version of the 
questionnaire into Persian. Both translations were 
reviewed by several medical experts in our department 
and a consensus version was back-translated into 
Italian by a native Italian speaker who was expert in 
Persian. This version was reviewed by Italian and 
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Persian authors and changes were made to the translated 
Persian version if there was any significant differences 
between the original and back-translated Italian versions. 
Finally, 11 patients were asked to fill the questionnaire 
and express their opinion regarding the difficulty in 
understanding and interpretation of the questions in a 
face to face interview. Since there was no significant 
problem at this point, the Persian version was used for 
remaining patients without further changes.  
 
Measurements 
Patients’ Urticaria Activity Score 7 (UAS-7) was 
used to evaluate the clinical severity in CU patients. 
14
 
UAS-7 is recommended by diagnosis guidelines of 
European Academy of Allergology and Clinical 
Immunology (EAACI), the Global Allergy and Asthma 
European Network (GA2LEN), the European 
Dermatology Forum (EDF), World Allergy Organization 
(WAO) 
14
 to assess the disease activity of CU. This 
system allocates a score of 0 to 3 to each of pruritus and 
wheals, according to their severity, as the most important 
symptoms of CU with a score between 0 and 6 for each 
day. This score is calculated for 7 consecutive days and 
the final score is between 0 and 42. 
 
Statistical Analysis 
The first step in the validation process of Persian 
version of CU-Q2oL was to determine the appropriate 
structure of scales. Exploratory Factor Analysis (EFA) 
was used to determine the scale of CU-Q2oL mainly due 
to the cultural aspects and since this questionnaire is 
new.
6
 Using Varimax factor rotation with Kaiser 
normalization, data were reduced into summary scores. 
The criterion applied to retain scales was an Eigen value 
> or = 1.0 for that scale. This analysis was performed to 
examine which scale is the most appropriate suitor for 
each of the items. The critical threshold for each item to 
meet this condition has been pre-set at 0.5.  
After determining scales, internal consistency was 
tested by calculating Cronbach α coefficient for each 
scale. Paired t-test was performed to evaluate the 
reliability of the questionnaire by comparing the results 
of CU-Q2oL scores at the baseline and one week later. 
Known-group validity was tested by determining 
whether the CU-Q2oL was able to distinguish between 
patients with different urticaria activity as measured by 
the UAS-7. The differences between group comparisons 
were determined using analysis of variance (ANOVA).  
Multiple linear regression analysis was performed to 
evaluate the probable significant predictors of different 
CU-Q2oL scores. Sex, age, duration and severity of 
disease, and the presence of angioedema were 
considered as independent variables while total and scale 
scores of CU-Q2oL were considered as dependent 
variables.  
All statistical analyses were performed using the 
SPSS version 21 (IBM New York, USA). A P-value 
lower than 0.05 was considered as statistically 
significant.  
 
RESULTS 
 
Patients’ Characteristics 
A total number of 110 patients (20 males and 90 
females) were enrolled in this study. The mean (SD) age 
of the patients was 33.6 (10.8) years ranging from 18 to 
67 years. Majority of the patients (69.1%) aged between 
20 and 40 years. The mean (SD) duration of disease was 
62.5 (96.3) months ranging from one month to 40 years. 
A considerable subgroup of patients (30.9%) had CU for 
more than 5 years. Out of 110 patients, 94 (85%) were 
receiving the standard treatment of CU at the time of the 
study. Angioedema was present in 75 (68.2%) patients. 
None of the patients reported any difficulty in 
understanding or answering the Persian version of CU-
Q2oL questionnaire. Most patients completed and 
returned the questionnaire in about 2-3 minutes and no 
patient needed more than 5 minutes in this process.  
 
Determination and Validation of Persian CU-Q2oL 
Scales 
Of the 110 CU patients enrolled in this study, no 
missing response in the CU-Q2oL questionnaire was 
observed. The factor analysis was performed using a 6 
factor structure for Persian CU-Q2oL data. The results of 
6 dimensional factor analyses are summarized in Table 
1. About 68% of the variance was explained by this 6 
factor structure higher than 59.9% of the original Italian 
version, 
9
 indicating a good validity. The determined sets 
of scales for Persian CU-Q2oL are shown in Table 2. 
The mean (SD) total CU-Q2oL was 58.43 (16.83). The 
mean (SD) score for factor I, II, III, IV, V and VI were 
56.33 (23.63), 59.45 (20.62), 67.94 (19.93), 51.76 
(20.49), 49.64 (21.92), and 49.92 (21.4), respectively. 
 
Internal Consistency 
Internal consistency results using the Cronbach’s α 
coefficient test for 6 scales showed an excessive 
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Table 1. Different levels of Scale determination for the Persian version of CU-Q2oL Questionnaire 
Component Initial Eigen values Rotation Sums of Squared Loadings 
 Total % of Variance Cumulative % Total % of Variance Cumulative % 
(A) Results of Varimax rotation with Kaiser normalization 
1 8.434 36.671 36.671 4.069 17.693 17.693 
2 1.965 8.543 45.214 3.258 14.166 31.859 
3 1.643 7.143 52.357 2.709 11.779 43.638 
4 1.403 6.099 58.456 2.104 9.149 52.787 
5 1.176 5.113 63.570 1.796 7.807 60.594 
6 1.034 4.497 68.067 1.719 7.473 68.067 
The criterion applied to retain scales was an eigen value > or = 1.0 for that scale.  
 
Item no. Item name Scales 
 
I II III IV V VI 
(B) Matrix of components resulting in 6 diverse scale solutions 
1 Pruritus 0.279 0.790 0.084 0.203 -0.015 0.002 
2 Wheals  0.089 0.800 0.125 0.283 0.031 0.138 
3 Eyes swell  0.180 0.200 -0.021 0.761 0.177 0.073 
4 Lips swell  0.128 0.110 -0.020 0.838 0.020 0.158 
5 Work  0.246 0.417 -0.034 -0.012 0.558 0.286 
6 Physical activities  0.106 0.005 0.180 0.086 0.726 -0.069 
7 Sleep  0.597 0.552 0.238 0.080 0.151 -0.118 
8 Spare time  0.392 0.634 0.274 -0.021 0.159 0.106 
9 Social relations  0.253 0.623 0.112 0.006 0.391 0.251 
10 Eating  0.198 0.180 0.616 0.518 0.109 0.020 
11 Difficulty falling asleep  0.754 0.335 0.130 0.076 0.144 -0.091 
12 Waking up at night  0.623 0.287 0.328 0.191 0.271 -0.133 
13 Diurnal tiredness  0.834 0.138 0.095 0.136 0.101 0.154 
14 Concentration  0.744 0.161 0.020 0.042 0.108 0.343 
15 Nervousness  0.733 0.071 0.146 0.219 0.030 0.333 
16 Feeling blue  0.531 0.265 0.319 0.033 -0.054 0.571 
17 Limit food  0.038 0.203 0.797 0.100 -0.075 0.093 
18 Embarrassed by signs  0.188 0.335 0.035 0.267 0.409 0.373 
19 Embarrassed in public  0.131 0.067 0.167 0.184 0.108 0.804 
20 Limits cosmetics  0.066 -0.169 0.601 0.042 0.386 0.114 
21 Limits clothes  0.315 0.240 0.632 -0.199 0.128 0.040 
22 Limits sport  0.255 0.129 0.577 -0.299 0.250 0.221 
23 Medication side-effects  0.044 0.255 0.338 0.249 0.423 0.180 
This indicates which scale is the most appropriate suitor for each of the items. The critical threshold for each item to meet this condition has been pre-
set at 0.5 (see bold values) 
 
consistancy for scales I and II (0.934 and 0.943, 
respectively), excellent for scale IV (0.837), 
respectable for scale III (0.796), minimally acceptable 
for scale VI (0.686), and undesirable for scale V 
(0.637). Although Cronbach’s α coefficient was below 
our desired value for scale V, since Baiardini et al. 
considered a Cronbach’s α higher than 0.5 as 
acceptable, we decided not to omit this scale.  
 
Reliability 
The mean (SD) total CU-Q2oL score was 52.49 (17.83) 
at the baseline and 53.2 (16.56) one week later. No 
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Table 2. Scales of the Persian CU-Q2oL 
Scale 
no. 
Scale name Questionnaire item 
no. 
Questionnaire item names 
I Functioning/ Mental status 5,6,9,14,15,22 Work, Physical activities,  Social relations,  Concentration,  
Nervousness,  Limits sport 
II Sleep/ Eating/ Embarrassment  7,10,11,12,13,18 Sleep,  Eating,  Difficulty falling asleep,  Waking up at 
night,  Diurnal tiredness,  Embarrassed by signs 
III Itching/ Mental status 1,2,16 Pruritus,  Wheals,  Feeling blue 
IV Limits/ Functioning 8,17,20 Spare time,  Limit food,  Limit cosmetics 
V Looks/ Embarrassment 4,19 Lips swell,  Embarrassed in public 
VI Looks/ Medication 3,23 Eyes swell,  Medication side-effects 
 
significant change in total CU-Q2oL score was 
observed during this period (P-value = 0.545). Similar 
to total score, no significant difference was observed in 
the scores of any of the 6 dimensions of CU-Q2oL at 
the baseline and re-test. 
 
Known-Group Validity 
The mean (SD) UAS-7 score was 25.34 (11.42). 
Patients were categorized into quartile groups 
according to their UAS-7 score. ANOVA test was 
performed to evaluate significance of differences in 
total CU-Q2oL score among these groups. The mean 
(SD) Total CU-Q2oL scores for these 4 quartile groups 
were 50.7 (14.5), 67.6 (13.1), 71.8 (18.7) and 67.2 
(19.3), respectively. Total CU-Q2oL score of 1st 
quartile was significantly different from 2nd, 3rd and 
4th quartiles (P=0.003, P<0.001, and P<0.001, 
respectively). However, no significant difference was 
observed among 2nd, 3rd and 4th quartiles. There was 
also a significant correlation between UAS-7 scores 
and total CU-Q2oL score using the Pearson correlation 
coefficient test (P<0.001, r=0.492). 
 
Multiple Linear Regressions 
None of the items including sex, age, and duration 
of disease was significant predictors of total CU-Q2oL 
scores or any of its 6 factors. In contrast, UAS-7 score 
and the presence of angioedema were significantly 
predictor of high CU-Q2oL scores. Table 3 presents the 
results of multiple linear regressions analysis. 
 
 
Table 3. Multiple linear regression analysis for the evaluation of the probable significant predictors of CU-Q2oL scores. 
 
I II III IV V VI 
Total CU-
Q2oL score 
Sex, Beta  
(P-value) 
0.001 (0.99) 0.02 (0.79) 0.1 (0.26) 0.24 (0.01*) 0.02 (0.81) 0.04 (0.68) 0.06 (0.44) 
Age, Beta  
(P-value) 
0.01 (0.88) -0.03 (0.69) 0.16 (0.08) -0.002 (0.98) -0.04 (0.68) 0.12 (0.2) 0.03 (0.72) 
Duration of 
disease, Beta 
(P-value) 
-0.14 (0.13) -0.14 (0.11) -0.13 (0.14) 0.06 (0.51) -0.08 (0.38) -0.09 (0.35) -0.15 (0.09) 
UAS-7, Beta  
(P-value) 
score 
0.36 (<0.001*) 0.46 (<0.001*) 0.46 (<0.001*) 0.27 (0.004*) 0.17 (0.07) 0.26 (0.005*) 0.48(<0.001*) 
Angioedema, 
Beta  
(P-value) 
-0.13 (0.17) -0.2 (0.02*) -0.08 (0.34) -0.05 (0.56) -0.32 (0.001*) -0.36 (<0.001*) -0.2 (0.02*) 
*: Statistically significant, Beta: standardized coefficients 
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DISCUSSION 
 
CU patients suffer a significant impairment in their 
QoL which is even considered to be equal to coronary 
artery disease by some authors.
8
 Evaluation of QoL in 
CU patients is an essential step to monitor the 
effectiveness of treatment both at the clinical setting 
and research projects on CU.
10
 Before the introduction 
of CU-Q2oL by Baiardini et al.
9
 in 2005, several 
generic as well as dermatology specific questionnaires 
were used to evaluate QoL in CU patients.  CU-Q2oL, 
as the sole disease-specific tool for measurement of 
QoL of CU, has been converted into several languages 
including Brazilian-Portuguese, German, Polish, 
Spanish and Turkish.
3,6,10-12
 The results of the current 
study, with an aim to adopt the CU-Q2oL questionnaire 
to Persian language with about 60 million native 
speakers and an estimated 110 million total speakers, 
showed a reliable and valid structure.   
The results of 6 dimensional factor analysis showed 
an acceptable validity for this structure. Although some 
studies persuaded to outline a Spanish and Turkish 
versions of CU-Q2oL decided to retain the original 6 
scales,
3,10
 others such as studies on the German and 
Polish versions of CU-Q2oL determined a new 6 scales 
structure according to the results of  their factor 
analysis.
6,11
 Moreover, Brazilian-Portuguese version of 
CU-Q2oL determined a 3-scale structure.
12
 After 
determination of Persian CU-Q2oL scales, several 
differences with the original study were observed. 
Factor I, functioning/ mental status, collected items 
related to activity and some items from mental status 
without considering the remaining 17 items. In contrast 
with the original Italian version,
9
 Persian speaking 
patients considered problem in concentration, 
nervousness and limited actions in sport in association 
with their function. This can be easily explained since 
these conditions highly affect the function and efficacy 
of patients both in doing their jobs and their day-to-day 
activities including exercise and performing any sports. 
Factor II includes items relating to sleep problems in 
addition to problems in eating and embarrassing by 
signs. It is noteworthy that there is a connection 
between sleeping and eating in Persian culture and 
many individuals may consider these 2 factors as 
measures for their quality of life. Factor III, itching/ 
mental status, consisted of pruritus and wheals which 
were both included in the original version in the 
category of pruritus
9
 in addition to feeling blue or 
depressed. In the German version of CU-Q2oL, there 
was also 2 other items, bothered by signs, and 
embarrassed in public, which were allocated in factor 
III in addition to pruritus and wheals of the original 
version.
6
 It seems that whereas German patients 
consider pruritus and wheals to result in being bothered 
and embarrassed in public, Persian speaking patients 
are more likely to feel depressed as a result of these 2 
physical symptoms of CU. Factor IV, includes 
impairments in spare time,  limitations in food,  
limitations in cosmetics. Factor V, includes looks/ 
embarrassment, lips swelling, and feeling embarrassed 
in public. This finding is in contrast with findings of 
German authors who suggested that lips swelling 
interfere with eating and does not result in feeling 
embarrassed.
6
 Factor VI, includes looks/ medication, 
eyes swelling, and medication side-effects.  
The 6-factor structure of Persian CU-Q2oL showed 
good validity since all scales had an acceptable 
consistency and all items seems to be placed properly 
into various scales based on the cultural background of 
Persian speaking people. In addition, all items were 
categorized according to the statistical analysis and no 
revision or editing was undertaken to change this 
desired structure. 
Total CU-Q2oL was significantly correlated with 
UAS-7 indicating the validity of this questionnaire. 
UAS-7 is widely used to access the activity and 
severity of CU.
6
 There was also a significant difference 
between the UAS-7 score of CU patients with a total 
CU-Q2oL score at the 1st quartile, with this score in 
individuals with a total CU-Q2oL score in the 2nd, 3rd, 
and 4th quartiles. Although CU patients in the higher 
quartiles showed higher disease activity as measured by 
UAS-7, this difference was not significant probably due 
to the low number of cases in each group and/or the 
narrow range of this item. The mean (SD) total CU-
Q2oL was 58.43 (16.83) in the current study, much 
higher than of reported values of Turkish and Spanish 
studies which reported a total CU-Q2oL around 25%. 
This higher total CU-Q2oL score was accompanied by 
a higher UAS-7 score in comparison to the mentioned 
studies which indicated worse quality of life in Persian 
speaking patients comparing to Turkish and Spanish 
speaking patients.
3,10
  
The results of multiple linear regression showed 
that UAS-7 was the predictor of total CU-Q2oL as well 
as all of its factors excluding factor V. This was 
expected as previous studies also reported UAS-7 as 
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the best predictor of CU-Q2oL scores since it presents 
the activity of CU.
6,11
 Although other studies did not 
show a significant prediction of CU-Q2oL scores by 
the presence of angioedema,
6,10,11
 this item was a 
significant predictor of total CU-Q2oL as well as 
factors II, V and VI. A simple explanation for this 
outcome is that factor V and VI are directly associated 
with swelling of lips and eyes. Factor II includes items 
regarding the sleep problems as well as problem in 
eating and the feeling of embarrassment by signs. It is 
likely for CU patients to feel embarrassed because of 
angioedema in addition to suffering from sleep 
difficulties. Although Młynek et al. reported sex as a 
predictor of CU-Q2oL scores,
6
 the analysis of the 
current studies as well as another study by Polish 
authors
11
 showed that neither sex, nor age, and duration 
of disease were significant predictors of total CU-Q2oL 
scores or any of its 6 factors. 
There are still many undiscovered areas in the 
pathogenesis as well as the treatment of CU. Treatment 
of CU is not effective in many cases and such patients 
suffer from psychological turbulences and experience a 
low QoL.
13,15,16
 Assessment of QoL in CU patients 
using a disease-specific tool such as CU-Q2oL is 
essential for the better management of disease and 
provides standard measurement for clinical researches 
on the therapeutic approaches.
10
  
The Persian version of CU-Q2oL is a valid and 
reliable tool to be used in the future clinical studies. 
Moreover, it can be used to compare the QoL in 
Persian speaking population with other patients around 
the world with available validated CU-Q2oL in their 
maternal language. Cultural considerations should be 
kept in mind in the process of validating this 
questionnaire into other languages especially regarding 
the determination of scales and patients’ view on their 
symptoms. Evaluation of minimum important 
difference of the Persian version of CU-Q2oL will be 
the subject of further studies.  
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